Who are GP combined with Tislelizumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gp-combined-with-tislelizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GP combined with Tislelizumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GP combined with Tislelizumab (GP combined with Tislelizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor combined with chemotherapy. Area: Oncology.

phase 3 PD-1 inhibitor combined with chemotherapy PD-1 (programmed death receptor 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GP combined with Tislelizumab (GP combined with Tislelizumab) — XIANG YANQUN. GP combined with Tislelizumab uses a chemotherapy backbone (likely gemcitabine/cisplatin) paired with an anti-PD-1 immunotherapy to kill cancer cells and enhance immune-mediated tumor destruction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GP combined with Tislelizumab TARGET	GP combined with Tislelizumab	XIANG YANQUN	phase 3	PD-1 inhibitor combined with chemotherapy	PD-1 (programmed death receptor 1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor combined with chemotherapy class)

XIANG YANQUN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP combined with Tislelizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/gp-combined-with-tislelizumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab